Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases

2021 ◽  
Author(s):  
Min-Wook Seo ◽  
Tae-Eun Park
Keyword(s):  
Neurodegenerative Diseases ◽  
Drug Carriers ◽  
Recent Advances

Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases

1998 ◽  
Vol 55 (4) ◽  
pp. 333-341 ◽  
Author(s):  
M. Barkats ◽  
A. Bilang-Bleuel ◽  
M.H. Buc-Caron ◽  
M.N. Castel-Barthe ◽  
O. Corti ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Neurodegenerative Diseases ◽  
Recent Advances ◽  
The Brain

scholarly journals Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4844
Author(s):  
Mareike Waldenmaier ◽  
Tanja Seibold ◽  
Thomas Seufferlein ◽  
Tim Eiseler
Keyword(s):  
Pancreatic Cancer ◽  
Extracellular Vesicles ◽  
Drug Carriers ◽  
Tumor Formation ◽  
Pancreatic Stellate Cells ◽  
Ductal Adenocarcinoma ◽  
Long Distance ◽  
Diagnosis And Prognosis ◽  
Recent Advances ◽  
Biomarker Analysis

Even with all recent advances in cancer therapy, pancreatic cancer still has a dismal 5-year survival rate of less than 7%. The most prevalent tumor subtype is pancreatic ductal adenocarcinoma (PDAC). PDACs display an extensive crosstalk with their tumor microenvironment (TME), e.g., pancreatic stellate cells, but also immune cells to regulate tumor growth, immune evasion, and metastasis. In addition to crosstalk in the local TME, PDACs were shown to induce the formation of pre-metastatic niches in different organs. Recent advances have attributed many of these interactions to intercellular communication by small extracellular vesicles (sEVs, exosomes). These nanovesicles are derived of endo-lysosomal structures (multivesicular bodies) with a size range of 30–150 nm. sEVs carry various bioactive cargos, such as proteins, lipids, DNA, mRNA, or miRNAs and act in an autocrine or paracrine fashion to educate recipient cells. In addition to tumor formation, progression, and metastasis, sEVs were described as potent biomarker platforms for diagnosis and prognosis of PDAC. Advances in sEV engineering have further indicated that sEVs might once be used as effective drug carriers. Thus, extensive sEV-based communication and applications as platform for biomarker analysis or vehicles for treatment suggest a major impact of sEVs in future PDAC research.

Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases

2018 ◽  
Vol 1044 ◽  
pp. 12-28 ◽  
Author(s):  
Camila Marchioni ◽  
Israel Donizeti de Souza ◽  
Vinicius Ricardo Acquaro ◽  
José Alexandre de Souza Crippa ◽  
Vitor Tumas ◽  
...  
Keyword(s):  
Neurodegenerative Diseases ◽  
Biological Samples ◽  
Recent Advances

scholarly journals Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies

Molecules ◽  
2019 ◽  
Vol 24 (5) ◽  
pp. 927 ◽  
Author(s):  
Justine Habault ◽  
Jean-Luc Poyet
Keyword(s):  
Tissue Specificity ◽  
Chemical Compounds ◽  
Drug Carriers ◽  
Cell Penetrating Peptides ◽  
Amino Acid Sequences ◽  
Recent Advances ◽  
Cell Penetrating ◽  
A Cell ◽  
Low Toxicity ◽  
Applied Biology

Cell-penetrating-peptides (CPPs) are small amino-acid sequences characterized by their ability to cross cellular membranes. They can transport various bioactive cargos inside cells including nucleic acids, large proteins, and other chemical compounds. Since 1988, natural and synthetic CPPs have been developed for applications ranging from fundamental to applied biology (cell imaging, gene editing, therapeutics delivery). In recent years, a great number of studies reported the potential of CPPs as carriers for the treatment of various diseases. Apart from a good efficacy due to a rapid and potent delivery, a crucial advantage of CPP-based therapies is the peptides low toxicity compared to most drug carriers. On the other hand, they are quite unstable and lack specificity. Higher specificity can be obtained using a cell-specific CPP to transport the therapeutic agent or using a non-specific CPP to transport a cargo with a targeted activity. CPP-cargo complexes can also be conjugated to another moiety that brings cell- or tissue-specificity. Studies based on all these approaches are showing promising results. Here, we focus on recent advances in the potential usage of CPPs in the context of cancer therapy, with a particular interest in CPP-mediated delivery of anti-tumoral proteins.

Recent Advances with Liposomes as Drug Carriers

2014 ◽  
pp. 79-119 ◽  
Author(s):  
Shravan Kumar Sriraman ◽  
Vladimir P. Torchilin
Keyword(s):  
Drug Carriers ◽  
Recent Advances

scholarly journals MECHANISMS OF COGNITIVE AND NEUROLOGICAL AGING

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S587-S587
Author(s):  
Catherine Kaczorowski
Keyword(s):  
Neurodegenerative Diseases ◽  
Neurological Function ◽  
Biological Aging ◽  
Recent Advances ◽  
Age Related

Abstract This session will focus on recent advances in understanding how biological aging impacts neurological function and risk of developing age-related neurodegenerative diseases.

Recent advances in compartmentalized synthetic architectures as drug carriers, cell mimics and artificial organelles

2017 ◽  
Vol 152 ◽  
pp. 199-213 ◽  
Author(s):  
M.J. York-Duran ◽  
M. Godoy-Gallardo ◽  
C. Labay ◽  
A.J. Urquhart ◽  
T.L. Andresen ◽  
...  
Keyword(s):  
Drug Carriers ◽  
Recent Advances
Sign in / Sign up

Export Citation Format

Share Document